Total trials
51
Active
5
Phase 3
2
Total enrollment
4,308
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Bazedoxifene Acetate | — | — | — | — | — | 1 | |
| NMDA receptor antagonist | — | — | — | — | — | 1 | |
| D-Cycloserine | — | — | — | — | — | 1 |
Next readouts
- 2025-12
- 2026-05-29
- 2026-12-31
Top conditions
- Heart Failure8
- Schizophrenia7
- Schizoaffective Disorder6
- HIV Infections4
- Major Depressive Disorder4
- Schizophreniform Disorder3
- Cystic Fibrosis3
- Human Papillomavirus3
Frequently asked questions about The Alfred
- How many clinical trials does The Alfred have on ClinicalTrials.gov?
- The Alfred is listed as the lead sponsor on 51 clinical trials in ClinicalTrials.gov, 5 of which are currently active (recruiting, enrolling, or ongoing).
- How many of The Alfred's trials are in Phase 3?
- 2 of The Alfred's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does The Alfred focus on?
- The Alfred's most-studied conditions on ClinicalTrials.gov are Heart Failure, Schizophrenia, Schizoaffective Disorder, HIV Infections, Major Depressive Disorder.
- When are The Alfred's next clinical trial readouts?
- The Alfred has 3 upcoming primary-completion readouts tracked here; the soonest is “A Novel Drug for Borderline Personality Disorder”, expected around 2025-12.